ONC-403-001
A Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma, or Alveolar Rhabdomyosarcoma.
OPEN
NMTRC014
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine DFMO)
OPEN
NMTRC012
PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
OPEN
NMTRC011
A Phase I Trial of Tolcapone and Oxaliplatin in Patients with Relapsed or Refractory Neuroblastoma
OPEN
NMTRC003B
A Phase II Preventative Trial of DFMO as a Single Agent in Patients with High Risk Neuroblastoma in Remission
CLOSED
NMTRC009
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers
OPEN
NMTRC010
A Phase I/II Trial of DFMO in Combination with Bortezomib in Patients with Relapsed or Refractory Neuroblastoma
OPEN
V0706
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma
OPEN TO THE FOLLOWING GROUPS: RELAPSE NEUROBLASTOMA MEDULLOBLASTOMA
NMTRC001
A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients with Refractory or Recurrent Neuroblastoma
CLOSED
NMTRCPG007
A Phase II, Open-label, Multi-center, Pilot Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients with Refractory Pontine Glioma
CLOSED
NMTRC002
A Phase I Trial for Refractory or Relapsed Neuroblastoma with DFMO Along and in Combination with Etoposide
CLOSED
NMTRC008
A Feasibility Trial using Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancer
CLOSED
TPI-287-11
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination with Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma
CLOSED
NMTRC001P
A Pilot Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma
CLOSED
NMTRC004
A Phase I/II Trial of TPI 287 in Patients with Refractory or Recurrent Neuroblastoma and Medulloblastoma
CLOSED
NMTRC005
A Randomized, Phase I/II trial of Irinotecan and Temozolomide compared to Irinotecan and Temozolomide in Combination with TPI 287 in Patients with Primary Refractory or Early Relapsed Neuroblastoma
CLOSED